Mdr1

ß2 adrenergic receptor

5-HT2A serotonergic receptor

Sulphonylurea receptor (SUR1)

HER2 receptor

Thymidylate synthase and dihydrofolate reductase

Cardiac ion channels (HERG, KvLQTI, hKCNE2)

Cholesteryl ester transport protein (CETP), lipoprotein lipase (LDL), ^-fibrinogen

Apolipoprotein E4

tumors

Low tissue expression

9 Receptor downregulation

Multiple

Altered ß-cell ATP-dependent potassium channel activity

Overexpression in some breast and other cancers

Overexpression in some tumor cells

Delayed cardiac repolarization

Adriamycin Paclitaxel

Other anti-neoplastics Digoxin

Anti-neoplastics

Verapamil

Terfenadine

Fexofenadine

Protease inhibitors (most)

Albuterol Ventolin

Clozapine Tolbutamide

Trastuzumab

5-Fluorouracil Methotrexate

Quinidine

Cisapride

Terfenadine

Disopyramide

Meflaquine

Clarithromycin

Pravastatin

Tacrine Simvastatin

Resistance to treatment

Possibly 9 plasma drug concentration, risk of toxicity

Y Response, poor control of asthma

Variable drug efficacy

Y Insulin response

Receptor overexpression associated with 9 drug efficacy

Overexpression linked to development of resistance to drug anti-metabolites in tumor cells

Long Q-T syndrome, arrhythmias, torsade de pointes

Polymorphisms associated with atherosclerosis progression and response to pravastatin

Presence of allele predicts poor response to tacrine, reduced cardiovascular mortality with simvastatin aCompi[ed from Ingleman-Sundberg et al. (1999), Meyer (2000), Evans and Relling (1999), Sadee (2000) and Manicelli et al. (2000) and references therein.

concentration after a single oral dose of the drug. Other substrates of Pgp include important drugs with narrow therapeutic indices, such as chemother-apeutic agents, cyclosporin A, verapamil, terfena-dine, fexofenadine and most HIV-1 protease inhibitors (Meyer, 2000). In addition, overexpression of MDR-1 in cancer tumors has been associated with resistance to adriamycin, paclitaxel and other anti-neoplastic agents, and additional similar extrusion pumps are reported to contribute to drug resistance in various tumors (Sadee, 2000).

Another potentially important gene family with a number of reported variants that may affect function is that of the biogenic amine transporters, which play a role in the regulation of neurotrans-mitter concentrations (including serotonin, dopa-mine and GABA) in synaptic transmission (Jonsson et al., 1998). These transporters are the direct target receptors for many drugs such as anti-depressants and cocaine; polymorphisms of the serotonin transporter, in particular, have been associated with the modulation of complex behavior (Heils et al., 1996) and may play a role in treatment with specific serotonin transporter inhibitors.

Mutations in other transporter-like proteins such as the sulfonylurea receptor (SUR) that regulates ATP-sensitive K + channels and insulin secretion and the Na+/H + exchanger (NHE1) that serves as one of the target receptors for amiloride (an anti-hypertensive diuretic) are being studied and may have clinical significance in modulating the activity of many medicines (Sadee, 2000).

Drug Free Life

Drug Free Life

How To Beat Drugs And Be On Your Way To Full Recovery. In this book, you will learn all about: Background Info On Drugs, Psychological Treatments Statistics, Rehab, Hypnosis and Much MORE.

Get My Free Ebook


Post a comment